GRAIL (GRAL) Altman Z2-Score: -2.67 (As of Jun. 26, 2026)


GRAL GRAIL Inc GRAL
12 GF Score
Price $66.58
! 2 Warning Signs
View Full Analysis

What is GRAIL Altman Z2-Score?

GRAIL GRAL +0.02% 12 Altman Z2-Score is -2.67 as of Jun. 26, 2026. GuruFocus rates GRAL with a GF Score™ of 12/100. The stock has 2 warning signs investors should review. Among 211 Medical Diagnostics & Research companies, GRAIL ranks worse than 69.19% on this metric.

Altman Z2-Score, also known as Z"-Score, is used to predict the likelihood that a non-manufacturing company (excluding property/financial company) will face bankruptcy within a two-year period.

Warning Sign:

GRAIL has a Altman Z2-Score of -2.67, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

The zones of discrimination were as such:

When Altman Z2-Score <= 1.1, it is in Distress Zones.
When Altman Z2-Score >= 2.6, it is in Safe Zones.
When Altman Z2-Score is between 1.1 and 2.6, it is in Grey Zones.

The historical rank and industry rank for GRAIL's Altman Z2-Score or its related term are showing as below:

GRAL' s Altman Z2-Score Range Over the Past 10 Years
Min: -8.92   Med: -3.78   Max: 12.76
Current: -2.67

During the past 6 years, GRAIL's highest Altman Z2-Score was 12.76. The lowest was -8.92. And the median was -3.78.


GRAIL  (NAS:GRAL) Altman Z2-Score Explanation

The original Z-Score model was based on publicly traded manufacturing companies while the Z2-Score, also known as Z"-score can be used for any type of company excluding property/financial companies. Both Z-Score and Z2-Score describes the financial health of a company, and its likelihood of financial distress.

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4_2, Net Worth (Total Stockholders Equity - Preferred Stock)/Total Liabilities (NW/TL): it compares a company’s stock net worth with its total liabilities and can be used to assess the extent of its reliance on debt.

Read more about Altman Z2-Score, the original research on Z-Score and the additional research on Z2-Score.


Be Aware

Altman Z2-Score does not apply to financial companies.


GRAIL Altman Z2-Score Related Terms


GRAIL Altman Z2-Score Historical Data

* Premium members only.

The historical data trend for GRAIL's Altman Z2-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GRAIL Altman Z2-Score Chart

GRAIL Annual Data
Trend Dec18 Dec19 Dec22 Dec23 Dec24 Dec25
Altman Z2-Score
Get a 7-Day Free Trial -4.69 12.76 5.23 -8.47 -2.79

GRAIL Quarterly Data
Dec18 Dec19 Jun20 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Altman Z2-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -8.92 -5.90 -6.28 -2.79 -2.67

GRAL vs VCYT, ADPT, TWST: Altman Z2-Score Comparison

For the Diagnostics & Research subindustry, GRAIL's Altman Z2-Score, along with its competitors' market caps and Altman Z2-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GRAIL Altman Z2-Score vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, GRAIL's Altman Z2-Score distribution charts can be found below:

* The bar in red indicates where GRAIL's Altman Z2-Score falls into.


GRAL
12GF Score
GRAIL Inc GRAL
Altman Z2-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

GRAIL Altman Z2-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Z2-Score, also known as Z"-Score is the Z-Score for non-manufacturing companies excluding property/financial companies.

GRAIL's Altman Z2-Score for today is calculated with this formula:

Z=6.56*X1+3.26*X2+6.72*X3+1.05*X4_2
=6.56*0.2863+3.26*-3.6757+6.72*-0.1839+1.05*8.2589
=-2.67

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z2-Score when X4_2 value is 0.

Trailing Twelve Months (TTM) ended in Mar. 2026:
Total Assets was $2,803.5 Mil.
Total Current Assets was $877.3 Mil.
Total Current Liabilities was $74.7 Mil.
Retained Earnings was $-10,304.9 Mil.
Pre-Tax Income was -127.523 + -116.518 + -118.718 + -152.856 = $-515.6 Mil.
Interest Expense was 0 + 0 + 0 + 0 = $0.0 Mil.
Total Liabilities was $302.8 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(877.347 - 74.709)/2803.474
=0.2863

X2=Retained Earnings/Total Assets
=-10304.868/2803.474
=-3.6757

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(-515.615 - 0)/2803.474
=-0.1839

X4_2=Net Worth/Total Liabilities
=(Total Stockholders Equity - Preferred Stock)/Total Liabilities
=(2500.686 - 0)/302.788
=8.2589

The zones of discrimination were as such:

Distress Zones - 1.1 < Grey Zones < 2.6 - Safe Zones

GRAIL has a Altman Z2-Score of -2.67 indicating it is in Distress Zones.

Frequently Asked Questions Learn more about Altman Z2-Score →
What does a Altman Z2-Score of -2.67 mean?
GRAIL (GRAL) has a Altman Z2-Score of -2.67 as of Jun. 26, 2026. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on GRAIL and its competitors. According to the industry distribution chart, GRAIL ranks #146 out of 211 companies in the Medical Diagnostics & Research industry, placing it in the top 69.2%.
Is GRAIL's Altman Z2-Score too high?
GRAIL's current Altman Z2-Score is -2.67. Based on the distribution chart, GRAIL ranks #146 out of 211 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, GRAIL has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does GRAIL's Altman Z2-Score compare to VCYT and ADPT?
According to the Medical Diagnostics & Research industry distribution chart, GRAIL ranks #146 out of 211 companies for Altman Z2-Score. This places GRAIL in the lower half of its industry. The industry median Altman Z2-Score is 1.66. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z2-Score for a Medical Diagnostics & Research company?
The median Altman Z2-Score among Medical Diagnostics & Research companies is 1.66, based on 211 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z2-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z2-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z2-Score mean?
A high Altman Z2-Score can signal that a stock is expensive relative to its fundamentals. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on GRAIL and its competitors. For the Medical Diagnostics & Research industry, the median Altman Z2-Score is 1.66 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GRAIL's current Altman Z2-Score is -2.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GRAIL stock overvalued right now?
GRAIL (GRAL) has a current Altman Z2-Score of -2.67. The current Altman Z2-Score is -2.67. GRAIL's overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z2-Score calculated?
Altman Z2-Score is calculated from a company's financial statements. For GRAIL (GRAL), the current Altman Z2-Score is -2.67 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

GRAIL Business Description

Other Exchanges NL0:Germany
Address 1525 O’Brien Drive, Menlo Park, CA, USA, 94025
GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages. It operates in one reportable operating segment which provides multi-cancer early detection testing and service.
12GF Score

Get the complete analysis for GRAL

Altman Z2-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$66.58
Price